SCHEMBL4143041

SCHEMBL4143041

O=C(O)Cc1ccc(NC2=NC(=O)/C(=C\c3cccc(-n4cncn4)c3)S2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUSP22 Q9NRW4 2/20 0.38
DUSP3 P51452 1/20 0.38
GRK6 P43250 1/20 0.35
KMT2A Q03164 5/20 0.34
MAPT P10636 5/20 0.34
MEN1 O00255 4/20 0.34
KDM4E B2RXH2 2/20 0.34
RECQL P46063 2/20 0.34
NSD2 O96028 1/20 0.34
POLB P06746 1/20 0.34
APEX1 P27695 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CISD1 Q9NZ45 1/20 0.34
CTSD P07339 2/20 0.33
ALDH1A1 P00352 4/20 0.33
HTT P42858 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143044 1.00 DUSP22 (0.38) DUSP22DUSP3GRK6KMT2AMAPT
SCHEMBL4121542 0.87 LMNA (0.43) DUSP22DUSP3KMT2AMAPTMEN1
SCHEMBL4121541 0.87 LMNA (0.43) DUSP22DUSP3KMT2AMAPTMEN1
SCHEMBL4138118 0.84 NSD2 (0.43) DUSP22DUSP3KMT2AMAPTMEN1
SCHEMBL4138121 0.84 NSD2 (0.43) DUSP22DUSP3KMT2AMAPTMEN1
SCHEMBL4134037 0.82 DUSP22 (0.48) DUSP22DUSP3KMT2AMAPTMEN1
SCHEMBL4134034 0.82 DUSP22 (0.48) DUSP22DUSP3KMT2AMAPTMEN1
SCHEMBL4133862 0.81 DUSP22 (0.49) DUSP22DUSP3POLBALDH1A1RAB9A
SCHEMBL4133860 0.81 DUSP22 (0.49) DUSP22DUSP3POLBALDH1A1RAB9A
SCHEMBL4128002 0.80 FGFR1 (0.45) DUSP22DUSP3ALDH1A1HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ DUSP22 85/4885DUSP3 66/4885GRK6 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.